These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26298289)

  • 1. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
    Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
    Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
    Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
    Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
    Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
    J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.
    Niu Y; Pan D; Shi D; Bai Q; Liu H; Yao X
    PLoS One; 2015; 10(12):e0145219. PubMed ID: 26677850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
    Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
    Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
    Shi XL; Li Y; Zhao LM; Su LW; Ding G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
    Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
    Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer therapy. Targeting the poison within.
    Smits VA; Gillespie DA
    Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
    Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
    Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.
    Zhou H; Jian Y; Leng Y; Liu N; Tian Y; Wang G; Gao W; Yang G; Chen W
    Int J Hematol; 2017 Mar; 105(3):318-325. PubMed ID: 27848179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
    Yokoyama T; Kitakami R; Mizuguchi M
    Eur J Med Chem; 2019 Apr; 167():153-160. PubMed ID: 30771603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potent and selective MTH1 inhibitors.
    Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and specific MTH1 inhibitors targeting gastric cancer.
    Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
    Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
    Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
    Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
    Kumar A; Kawamura T; Kawatani M; Osada H; Zhang KYJ
    Chem Biol Drug Des; 2017 Jun; 89(6):862-869. PubMed ID: 27863017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
    Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
    Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere.
    Vivero-Escoto JL; Slowing II; Wu CW; Lin VS
    J Am Chem Soc; 2009 Mar; 131(10):3462-3. PubMed ID: 19275256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
    Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
    ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
    Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.